Please try another search
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It’s product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Gilles Avenard | 72 | 2021 | Founder, CEO & Director |
Alain H. Munoz | 74 | 2021 | Independent Chairman of the Board |
Catherine Boule | 46 | - | Director |
Jean-Pierre Cazenave | 80 | 2018 | Independent Board Member |
James Patrick Stearns | 44 | 2022 | Observer |
Guillaume Heynen | 78 | 2022 | Observer |
Patricia Zilliox | 67 | 2023 | Independent Director |
Alain Parthoens | 64 | 2022 | Director |
Rinaldo Del Bono | 84 | 2021 | Director |
Leila Nicolas | 43 | - | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review